BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

801 related articles for article (PubMed ID: 25538019)

  • 1. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma.
    Herman JM; Chang DT; Goodman KA; Dholakia AS; Raman SP; Hacker-Prietz A; Iacobuzio-Donahue CA; Griffith ME; Pawlik TM; Pai JS; O'Reilly E; Fisher GA; Wild AT; Rosati LM; Zheng L; Wolfgang CL; Laheru DA; Columbo LA; Sugar EA; Koong AC
    Cancer; 2015 Apr; 121(7):1128-37. PubMed ID: 25538019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safety.
    Gurka MK; Collins SP; Slack R; Tse G; Charabaty A; Ley L; Berzcel L; Lei S; Suy S; Haddad N; Jha R; Johnson CD; Jackson P; Marshall JL; Pishvaian MJ
    Radiat Oncol; 2013 Mar; 8():44. PubMed ID: 23452509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer.
    Schellenberg D; Goodman KA; Lee F; Chang S; Kuo T; Ford JM; Fisher GA; Quon A; Desser TS; Norton J; Greco R; Yang GP; Koong AC
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):678-86. PubMed ID: 18395362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-reported outcomes of a multicenter phase 2 study investigating gemcitabine and stereotactic body radiation therapy in locally advanced pancreatic cancer.
    Rao AD; Sugar EA; Chang DT; Goodman KA; Hacker-Prietz A; Rosati LM; Columbo L; O'Reilly E; Fisher GA; Zheng L; Pai JS; Griffith ME; Laheru DA; Iacobuzio-Donahue CA; Wolfgang CL; Koong A; Herman JM
    Pract Radiat Oncol; 2016; 6(6):417-424. PubMed ID: 27552809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unresectable locally advanced pancreatic cancer: a multimodal treatment using neoadjuvant chemoradiotherapy (gemcitabine plus stereotactic radiosurgery) and subsequent surgical exploration.
    Polistina F; Costantin G; Casamassima F; Francescon P; Guglielmi R; Panizzoni G; Febbraro A; Ambrosino G
    Ann Surg Oncol; 2010 Aug; 17(8):2092-101. PubMed ID: 20224860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer.
    Schellenberg D; Kim J; Christman-Skieller C; Chun CL; Columbo LA; Ford JM; Fisher GA; Kunz PL; Van Dam J; Quon A; Desser TS; Norton J; Hsu A; Maxim PG; Xing L; Goodman KA; Chang DT; Koong AC
    Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):181-8. PubMed ID: 21549517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer.
    Mahadevan A; Jain S; Goldstein M; Miksad R; Pleskow D; Sawhney M; Brennan D; Callery M; Vollmer C
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):735-42. PubMed ID: 20171803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes and prognostic factors of stereotactic body radiation therapy combined with gemcitabine plus capecitabine for locally advanced unresectable pancreatic cancer.
    Shen ZT; Zhou H; Li AM; Ji XQ; Jiang CC; Yuan X; Li B; Zhu XX; Huang GC
    J Cancer Res Clin Oncol; 2020 Feb; 146(2):417-428. PubMed ID: 31667573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SBRT in unresectable advanced pancreatic cancer: preliminary results of a mono-institutional experience.
    Tozzi A; Comito T; Alongi F; Navarria P; Iftode C; Mancosu P; Reggiori G; Clerici E; Rimassa L; Zerbi A; Fogliata A; Cozzi L; Tomatis S; Scorsetti M
    Radiat Oncol; 2013 Jun; 8():148. PubMed ID: 23799996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiagent Chemotherapy and Stereotactic Body Radiation Therapy in Patients with Unresectable Pancreatic Adenocarcinoma: A Prospective Nonrandomized Controlled Trial.
    Hill CS; Rosati L; Wang H; Tsai HL; He J; Hacker-Prietz A; Laheru DA; Zheng L; Sehgal S; Bernard V; Le DT; Pawlik TM; Weiss MJ; Narang AK; Herman JM
    Pract Radiat Oncol; 2022; 12(6):511-523. PubMed ID: 35306231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial.
    Zhu X; Cao Y; Liu W; Ju X; Zhao X; Jiang L; Ye Y; Jin G; Zhang H
    Lancet Oncol; 2021 Aug; 22(8):1093-1102. PubMed ID: 34237249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymphocyte-Sparing Effect of Stereotactic Body Radiation Therapy in Patients With Unresectable Pancreatic Cancer.
    Wild AT; Herman JM; Dholakia AS; Moningi S; Lu Y; Rosati LM; Hacker-Prietz A; Assadi RK; Saeed AM; Pawlik TM; Jaffee EM; Laheru DA; Tran PT; Weiss MJ; Wolfgang CL; Ford E; Grossman SA; Ye X; Ellsworth SG
    Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):571-9. PubMed ID: 26867885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conventionally fractionated radiation therapy versus stereotactic body radiation therapy for locally advanced pancreatic cancerĀ (CRiSP): An international systematic review and meta-analysis.
    Tchelebi LT; Lehrer EJ; Trifiletti DM; Sharma NK; Gusani NJ; Crane CH; Zaorsky NG
    Cancer; 2020 May; 126(10):2120-2131. PubMed ID: 32125712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baseline metabolic tumor volume and total lesion glycolysis are associated with survival outcomes in patients with locally advanced pancreatic cancer receiving stereotactic body radiation therapy.
    Dholakia AS; Chaudhry M; Leal JP; Chang DT; Raman SP; Hacker-Prietz A; Su Z; Pai J; Oteiza KE; Griffith ME; Wahl RL; Tryggestad E; Pawlik T; Laheru DA; Wolfgang CL; Koong AC; Herman JM
    Int J Radiat Oncol Biol Phys; 2014 Jul; 89(3):539-46. PubMed ID: 24751410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Image-guided stereotactic radiosurgery for locally advanced pancreatic adenocarcinoma results of first 85 patients.
    Didolkar MS; Coleman CW; Brenner MJ; Chu KU; Olexa N; Stanwyck E; Yu A; Neerchal N; Rabinowitz S
    J Gastrointest Surg; 2010 Oct; 14(10):1547-59. PubMed ID: 20839073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 1 Dose Escalation Study of SBRT Using 3 Fractions for Locally Advanced Pancreatic Cancer.
    Reyngold M; Karam SD; Hajj C; Wu AJ; Cuaron J; Lobaugh S; Yorke ED; Dickinson S; Jones B; Vinogradskiy Y; Shukla-Dave A; Do RKG; Sigel C; Zhang Z; Crane CH; Goodman KA
    Int J Radiat Oncol Biol Phys; 2023 Sep; 117(1):53-63. PubMed ID: 36918130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer.
    Oar A; Lee M; Le H; Wilson K; Aiken C; Chantrill L; Simes J; Nguyen N; Barbour A; Samra J; Sjoquist KM; Moore A; Espinoza D; Gebski V; Yip S; Chu J; Kneebone A; Goldstein D
    BMC Cancer; 2021 Aug; 21(1):936. PubMed ID: 34412605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Single-Institution Experience.
    Moningi S; Dholakia AS; Raman SP; Blackford A; Cameron JL; Le DT; De Jesus-Acosta AM; Hacker-Prietz A; Rosati LM; Assadi RK; Dipasquale S; Pawlik TM; Zheng L; Weiss MJ; Laheru DA; Wolfgang CL; Herman JM
    Ann Surg Oncol; 2015 Jul; 22(7):2352-8. PubMed ID: 25564157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful adjuvant bi-weekly gemcitabine chemotherapy for pancreatic cancer without impairing patients' quality of life.
    Toyama Y; Yoshida S; Saito R; Kitamura H; Okui N; Miyake R; Ito R; Son K; Usuba T; Nojiri T; Yanaga K
    World J Surg Oncol; 2013 Jan; 11():3. PubMed ID: 23302293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction gemcitabine and stereotactic body radiotherapy for locally advanced nonmetastatic pancreas cancer.
    Mahadevan A; Miksad R; Goldstein M; Sullivan R; Bullock A; Buchbinder E; Pleskow D; Sawhney M; Kent T; Vollmer C; Callery M
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e615-22. PubMed ID: 21658854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.